Canada Authorizes First Generic Ozempic, Paving the Way for Drastic Price Cuts
Ottawa, Wednesday, 29 April 2026.
Canada’s landmark approval of Dr. Reddy’s generic Ozempic marks a G7 first, challenging Novo Nordisk’s monopoly and potentially slashing patient medication costs by up to 90 percent.
A Milestone in Market Dynamics
On April 21, 2026, Health Canada issued a Notice of Compliance to Indian pharmaceutical manufacturer Dr. Reddy’s Laboratories, authorizing an injectable generic form of semaglutide [3]. The regulatory body publicly confirmed the approval on April 28, 2026, marking Canada as the first G7 nation to authorize a generic version of Novo Nordisk’s blockbuster drug, Ozempic [1][2]. The approval arrives roughly four months after Novo Nordisk’s Canadian patent for semaglutide expired in January 2026, officially opening the door for generic competitors in the North American market [2][3].
The Economics of Access
The introduction of a generic alternative is poised to significantly alter the financial landscape for patients and healthcare systems alike [2]. In 2025 alone, Ozempic generated CAD 2.9 billion in sales within Canada [3]. Prior to this generic approval, a monthly supply of Ozempic or its sister weight-loss drug, Wegovy, cost Canadian patients between CAD 300 and CAD 400 depending on the dosage, with the standard four-week list price for Ozempic sitting at CAD 228 [2][3]. Under the pan-Canadian Pharmaceutical Alliance framework, the introduction of a single generic competitor typically reduces the price to 75 percent of the brand-name list price, suggesting an initial generic price of CAD 171 for a four-week supply [3].
Looming Competition and Global Ripples
Dr. Reddy’s is merely the vanguard of a broader wave of generic GLP-1 receptor agonists. Health Canada is currently reviewing eight additional applications for generic semaglutide, with further decisions expected in the coming weeks and months [1][2]. Among the anticipated entrants is Swiss pharmaceutical company Sandoz, which announced in November 2025 its intention to launch a generic Ozempic in Canada by June 2026 [alert! ‘Status of Sandoz launch remains pending as of April 2026’] [1]. This influx of generic alternatives compounds the mounting pressure on Novo Nordisk, which is already battling for market share against Eli Lilly’s rival GLP-1 medications, Mounjaro and Zepbound [1].
Clinical Cautions Amidst Expanding Reach
While the financial barrier to entry is lowering, medical professionals are urging caution regarding the drug’s widespread utilization. Between one million and three million Canadian adults are currently reported to be taking GLP-1 medications, a figure expected to surge as generic options increase affordability [2][3]. Stephen Glazer, medical director of bariatric programs at Hennick Humber Hospital in Toronto, highlighted the previous cost barriers, noting the emotional toll of patients being forced to abandon treatment due to expense [3]. For many patients relying on partial benefit coverage or paying entirely out of pocket, the generic approval represents a vital lifeline [2][3].